Marimastat: the clinical development of a matrix metalloproteinase inhibitor

Bibliography

• CHAMBERS AF: Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. (1997) 89:1260–1270.
   PubMed Web of Science ®Google Scholar
• GOMEZ DE, ALONSO AF, YOSHIJI H, THORGEIRSSON UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. (1997) 74:111–122.
   PubMed Web of Science ®Google Scholar
• BROWN PD: Matrix metalloproteinase inhibitors in the treatment of cancer. Med. Oncol. (1997) 14:1–10.
   PubMed Web of Science ®Google Scholar
• NELSON AR, FINGLETON B, ROTHENBERG ML, MATRISIAN LM: Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol. (2000) 18 :1135–1149.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review concentrating on the biologicaleffect of matrix metalloproteinase inhibitors.
   Google Scholar
• STERNLICHT M, LOCHTE A, SYMPSON C et al.: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell (1999) 98:137–146.
   PubMed Web of Science ®Google Scholar
• AN Z, WANG X, WILMOTT N et al: Conversion of ahighly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metallo-proteinase inhibitor. Clin. Exp. Metastasis (1997) 15:184–195.
   PubMed Web of Science ®Google Scholar
• ECCLES SA, BOX GM, COURT WJ et al: Control oflymphatic and hematogenous metastases of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. (1996) 66:2815–2822.
   Google Scholar
• REICH R, THOMPSON EW, IWAMOTO Y et al: Effects ofinhibitors of plasminogen activator, serine proteases and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res. (1988) 48:3307–3312.
   PubMed Web of Science ®Google Scholar
• DAVIES B, BROWN PD, EAST N, CRIMMIN M, BALKWILL F: A synthetic matrix metalloproteinase inhibitor decreases tumour burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. (1993) 53:2087–2091.
   PubMed Web of Science ®Google Scholar
• •Important preclinical work providing basis for role of matrix metalloproteinase inhibitors.
   Google Scholar
• WANG X, FU X, BROWN PD, CRIMMIN MJ, HOFFMAN RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in patient-like orthotopic model in nude mice. Cancer Res. (1994) 54:4726–4728.
   PubMed Web of Science ®Google Scholar
• WATSON SA, MORRIS TM, PARSONS SL, STEELE RJ, BROWN PD: Therapeutic effect of the matrix metallo-proteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br. J. Cancer (1996) 74:1354–1358.
   PubMed Web of Science ®Google Scholar
• SLEDGE GW, QULALI M, GOULET R, BONE EA, FIFE R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst. (1995) 87:1546–1550.
   PubMed Web of Science ®Google Scholar
• ZERVOS EE, NORMAN JG, GOWER WR, FRANZ MG, ROSEMURGY AS: Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J. Surg. Res. (1997) 69:367–371.
   PubMed Web of Science ®Google Scholar
• CHIRIVI RG, GAROFALO A, CRIMMIN MJ et al.: Inhibition of the metastatic spread and growth of B 16-BI6 murine melanoma by a synthetic matrix metalloprote-inase inhibitor. Int. J. Cancer (1994) 58:460–464.
   PubMed Web of Science ®Google Scholar
• DECLERCK YA, PEREZ N, SHIMADA H et al.: Inhibition ofinvasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. (1992) 52:701–708.
   PubMed Web of Science ®Google Scholar
• KNOX JD, BRETTON L, LYNCH T, BOWDEN GT, NAGLERB: Synthetic matrix metalloproteinase inhibitor BB-94 inhibits the invasion of neoplastic human prostate cells in a mouse model. Prostate (1998) 35:248–254.
   PubMed Web of Science ®Google Scholar
• KIM J, YU W, KOVALSKI K, OSSOWSKI L: Requirementfor specific proteases in cancer cell intravasation as revealed by a novel semi-quantitative PCR-based assay. Cell (1998) 94:353–362.
   PubMed Web of Science ®Google Scholar
• ANDERSON IC, SHIPP MA, DOCHERTY AJ, TEICHER BA: Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res. (1996) 56:715–718.
   PubMed Web of Science ®Google Scholar
• GIAVAZZI R, GAROFALO A, LUCCHINI V et al.: Batimastat, a synthetic inhibitor of matrix metallopro-teinases, potentiates the anti-tumour activity of cisplatin in ovarian carcinoma x en ografts. Clin. Cancer Res. (1998) 4:985–992.
   PubMed Web of Science ®Google Scholar
• MILLAR AW, BROWN PD, MOORE J et al.: Results of single and repeat dose studies of the oral matrix metallopro-teinase inhibitor marimastat in healthy male volunteers. Br. J. Clin. Pharmacol (1998) 45:21–26.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, POOLE C, PRIMROSE J et al.: Combined analysis of studies of the effects of the Matrix Metallo-proteinase inhibitor Marimastat on serum tumour markers in advanced cancer: Selection of a biologi-cally active and tolerable dose for longer-term studies. Clin. Cancer Res. (1998) 4:1101–1109.
   PubMed Web of Science ®Google Scholar
• ••Overview of the initial Phase I/II trials and introduces theconcept of surrogate markers and biological effect.
   Google Scholar
• WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M eta].: Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Onco/. (1998) 16:2150–2156.
   Google Scholar
• •One of the first descriptions of the musculoskeletal pain, which is the main side effect of marimastat.
   Google Scholar
• TIERNEY GM, GRIFFIN NR, STUART RC et al.: A pilot study of the safety and effects of the matrix metalloprote-inase inhibitor marimastat in gastric cancer. Eur. Cancer (1999) 35:563–568.
   PubMed Web of Science ®Google Scholar
• BODURTHA A, EISENHAUSER E, STEWARD W etal.: Phase I-II study of marimastat (BB-2516) in patients with metastatic melanoma. Proc. ASCO (1997) 16:493a.
   Google Scholar
• MILLER KD, GRADISHAR WJ, SCHUCHTER LM et al: A randomized Phase II pilot trial of adjuvant marimastat in patients with early breast cancer. Proc. ASCO (2000) 19:96a.
   Google Scholar
• ADAMS MT, THOMAS H: A Phase I study of the matrix metalloproteinase inhibitor, marimastat, adminis-tered concurrently with carboplatin, to patients with relapsed ovarian cancer. Proc. ASCO (1998) 17:217a.
   Google Scholar
• O'REILLY S, MANI S, RATAIN MJ et al: Schedules of 5FU and the matrix metalloproteinase, marimastat: A Phase I study. Proc. ASCO (1998) 17:217a.
   Google Scholar
• CARMICHAEL J, LEDERMANN JA, WOLL PJ, GULLIFORD T, RUSSEL RC: A Phase lb study of concurrent administra-tion of marimastat and gemcitabine in non-resectable pancreatic cancer. Proc. ASCO (1998) 17:232a.
   Google Scholar
• ANDERSON I, SUPKO J, EDER J et al: Pilot pharmacoki-netic study of marimastat in combination with carboplatin/paclitaxel in patients with metastatic or locally advanced inoperable non-small cell lung cancer (NSCLC). Proc. ASCO (1999) 18:187a.
   Google Scholar
• GRADISHAR W, VONROENN J, COBLEIGH M et al: APhase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer. Proc. ASCO (1999) 18:125a.
   Google Scholar
• JONES PH, ELLIOT M, DOBBS N et al.: Phase I/II study of combination antiangiogenesis therapy with marimastat, captopril and fragrnin. Proc. ASCO (1999) 18 :447a.
   Google Scholar
• ROSEMURGY A, BUCKELS R, CHARNLEY R et al.: A randomised study comparing marimastat to gemcita-bine as first-line therapy in patients with non-resectable pancreatic cancer. Proc. ASCO (1999) 18 :261a.
   Google Scholar
• •The first randomised controlled study of an MMPI in patients.
   Google Scholar
• FIELDING J, SCHOLEFIELD J, CUTSERN R, THORLACIUS- USSING 0, HOVENDAL C: A randomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc. ASCO (2000) 19:240a.
   Google Scholar
• •First report of a placebo-controlled Phase III randomised study of marimastat.
   Google Scholar
• BRITISH BIOTECH PLC: Results of marimastat study 193in advanced pancreatic cancer. Press Release (2000) January 25.
   Google Scholar
• BRITISH BIOTECH PLC: Results of marimastat study 131in glioblastomamultiforme. Press Release (2000) June 23. Anne L Thomas & William P Steward
   Google Scholar